Theranekron for treatment of endometriosis in a rat model compared with medroxyprogesterone acetate and leuprolide acetate

Dolapcioglu K, Kenan Dolapçıoğlu, Kenan Dolapcioglu, Gokhan Dogruer, Dogruer G, Gökhan Doğruer, Sule Ozsoy, Şule Özsoy, Ozsoy S, Yaşar Ergün, Ergun Y, Yasar Ergun, Ciftci S, Sinasi Ciftci, Şinasi Çiftçi, Soylu Karapinar O, Oya Soylu Karapınar, Oya Soylu Karapinar, Erdoğan Aslan, Erdogan ASLAN
European journal of obstetrics, gynecology, and reproductive biology · 2013 · vol. 170(1) , pp. 206–210 · doi:10.1016/j.ejogrb.2013.05.026 · PMID:23827690 · W1977264199
article OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

This study investigated the efficacy of Theranekron in treating endometriosis in a rat model, comparing its effects to medroxyprogesterone acetate and leuprolide acetate.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectivesThe aim of this study was to compare the effects of theranekron, medroxyprogesterone acetate (MPA), and leuprolide acetate (LA) on surgically induced endometriosis in a rat model.Study designEndometriosis was surgically induced in forty female rats during estrus. After 3 weeks, a second operation was performed and the rats were randomized using a randomization table into theranekron, MPA, LA, and control groups. These treatments were continued for 3 weeks. A third operation was performed to evaluate treatment results. Then, the experimental treatments were halted and estrogen was initiated again to maintain estrus. After three additional weeks; i.e. after 9 weeks, the recurrence rate of endometrial foci was evaluated in a fourth operation and the rats were sacrificed. The volume of endometriotic foci and histopathology scores before and after treatment were compared.ResultsThe respective mean volumes of the endometriotic foci after 3, 6, and 9 weeks were 86.4±21.2, 16.4±8.2, and 20.1±9.6 mm(3) in the theranekron group, 78.3±20.4, 42.6±13.5, and 66.7±16.2 mm(3) in the MPA group, and 91.8±30.2, 34.4±11.4, and 72.4±21.9 mm(3) in the LA group. The respective mean histopathology scores were 2.4±0.6, 1.8±0.6, and 1.6±0.6 in the theranekron group, 2.5±0.8, 2.0±1.1, and 2.7±1.0 in the MPA group, and 2.3±0.5, 2.1±1.2, 2.4±0.8 in the LA group. After 9 weeks, the mean volume of endometriotic foci and histopathology scores were significantly lower in the theranekron group.ConclusionsTheranekron caused more evident regression of endometriotic foci than MPA or LA in a rat model. After stopping the theranekron treatment, the recurrence rate was also lower than that of the other groups.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antineoplastic Agents, Hormonal Endometriosis Leuprolide Medroxyprogesterone Acetate Spider Venoms Animals Antineoplastic Agents, Hormonal Disease Models, Animal Endometriosis Endometriosis Endometrium Endometrium Female Leuprolide Medroxyprogesterone Acetate Random Allocation Rats Secondary Prevention Spider Venoms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Cited by (4)

Source provenance

europepmc
last seen: 2026-08-06T06:07:45.168820+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:59.468224+00:00
unpaywall
last seen: 2026-08-06T06:41:17.185923+00:00
License: CC0 · commercial use OK